The interpretation of longitudinal studies/therapeutic trails to test disease-modifying interventions is challenged by the fact that some AD cases with tau rich regions do not show tracer equilibrium within a comparable time frame [38, 42]. This evidence concerns the gene MAPT and Alzheimer disease.